The limited number of patients with such tumours in the first generation of adjuvant trastuzumab trials has been an obstacle to drawing definitive conclusions regarding their response to HER2 targeted therapy, and clinical data for this unusual category of cases are desperately required. Here, ERBB2 is linked to neoplasm.